Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma

Minczeles, Noémie S; Bos, Eelke M.; Leeuw, Reinoud C. de; Kros, Johan M.; Konijnenberg, Mark; Bromberg, Jacoline E C; Herder, Wouter W. de; Dirven, Clemens; Hofland, Johannes; Brabander, Tessa

doi:10.1007/s00259-022-06044-9

Cited by 8 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies confirmed the poor outcome for high grade meningiomas treated with RLT [68,71]. Conversely, Minczeles et al [72] documented both a decline in tumor growth rate and a relatively good disease control in 15 patients who received [ 177 Lu]Lu-DOTATATE, with low systemic toxicity. Probably, baseline SSTR2 expression may play a key role in the correct selection of patients with aggressive meningiomas to address to RLT.…”

Section: Meningiomas Cup-nets and Other Rare Tumors Overexpressing Sstrmentioning

confidence: 94%

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

et al. 2023

View full text Add to dashboard Cite

Lutathera® is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine neoplasms (NET) can be treated with Lutathera®. Conversely, patients with SSTR-positive disease arising from outside the gastroenteric region do not currently have access to Lutathera® treatment despite several papers in the literature reporting the effectiveness and safety of RLT in these settings. Moreover, patients with well-differentiated G3 GEP-NET are also still “Lutathera orphans”, and retreatment with RLT in patients with disease relapse is currently not approved. The aim of this critical review is to summarize current literature evidence assessing the role of Lutathera® outside the approved indications. Moreover, ongoing clinical trials evaluating new possible applications of Lutathera® will be considered and discussed to provide an updated picture of future investigations.

show abstract

Section: Meningiomas Cup-nets and Other Rare Tumors Overexpressing Sstrmentioning

confidence: 94%

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Radionuclide therapy is well tolerated for refractory meningiomas and promising, essentially in WHO grade I and II. [7][8][9] However, due to the rapid alteration and progression, this treatment was not feasible. Follow-up at third month under new antiangiogenic agent showed an overall morphological progression with a collapse of the uptake on the contrast-enhanced 68 Ga-DOTATOC PET/CT (D panel with MIP and PET/CT).…”

mentioning

confidence: 99%

“…Epithelial membrane antigen staining ( C panel, lowest picture with original magnification ×200) was positive in immunohistochemistry. Radionuclide therapy is well tolerated for refractory meningiomas and promising, essentially in WHO grade I and II 7–9 . However, due to the rapid alteration and progression, this treatment was not feasible.…”

mentioning

confidence: 99%

Transformation From Atypical to Anaplastic Metastatic Meningioma

Morcet-Delattre,

Meneret,

Coue

et al. 2023

Clin Nucl Med

View full text Add to dashboard Cite

World Health Organization (WHO) grade III anaplastic meningioma is scarce. In this way, most studies compared WHO grade I and II. Otherwise, some authors are uncertain about using 18F-FDG as a diagnostic tool to estimate the WHO grade, especially high. We report the case from a man with a grading tumor evolution from WHO grade II atypical to grade III anaplastic metastatic meningioma. This turning point was imaged using 68Ga-DOTATOC and 18F-FDG. Diagnostic was confirmed by histology. The case underlines the unparalleled power of molecular imaging characterized by high sensitivity staging and spectacular avidity changing relationship with grading tumor evolution.

show abstract